Before that (pictured left in 2020), nutrition and exercise alone didn't work and she developed high blood pressure ... lifestyle changes. She argues that health insurers will still incur costs in the ...

Austin Chiang, MD, MPH: One innovation that's happening in my specialty of gastroenterology is artificial intelligence. Ben ...

Use of GLP-1 weight ... in those taking of GLP-1 receptor agonists. They found an increased risk of 19 health outcomes including symptoms of gastrointestinal conditions such as nausea and vomiting, ...

The downside was finding that the drugs produced an increased risk of gastrointestinal disorders, low blood pressure ... sleep apnea FDA says shortage of GLP-1 drug tirzepatide is over Merck ...

However, the conclusion that GLP-1 use in some way drives greater PAP (positive airway pressure) therapy initiation ... the potential upside of changes in market dynamics that are uncertain ...

Systemic medications, particularly selective beta blockers and calcium channel blockers, can significantly influence intraocular pressure (IOP) over time, according to study results published in ...

GLP-1 drugs ... high blood pressure does, Low Wang says. “It’s likely to be a lifelong medication,” she notes. “It is a drug that we anticipate will require long-term use,” Hurtado ...

The downside was finding that the drugs produced an increased risk of gastrointestinal disorders, low blood pressure ... glucagon-like peptide-1 receptor agonists (GLP-1RA) and include Mounjaro ...

“We’ve known for a long time that people who have a lower body mass index are likely to have lower blood pressure, likely to help lower ... Budson said the results could inform the use of GLP-1 drugs, ...

an uptick in use of GLP-1 drugs suppressing consumption or other “potential regulatory changes,” such as state or federal bans on specific food additives, executives brashly declared yesterday.

The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...